Functional design of potential inhibitors of human immunodeficiency virus (HIV) binding to CD4+ target cells: A molecular model of GP120 predicts ligand binding

Drug Design and Discovery

Volumn 14, Issue 2, 1996, Pages 103-114

  Gabriel, Jerome L ^a   Mitchell, William M ^b  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CD4 surrogate ligands; HIV gp120 structure; HIV inhibition; Inhibitors of gp120 CD4 binding; Molecular modeling

Indexed keywords

CD4 ANTIGEN; CELL RECEPTOR; GLYCOPROTEIN GP 120; VIRUS PROTEIN;

ARTICLE; BINDING SITE; COMPUTER SIMULATION; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS; LIGAND BINDING; MOLECULAR MODEL; NONHUMAN; REGRESSION ANALYSIS; VIRUS REPLICATION;

ANTIGENS, CD4; AURINTRICARBOXYLIC ACID; BINDING SITES; COMPUTER SIMULATION; DRUG DESIGN; HIV; HIV ENVELOPE PROTEIN GP120; LIGANDS; MODELS, MOLECULAR; SURAMIN; TANNINS;

EID: 0030479015     PISSN: 10559612     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Gabriel, J.L. and Mitchell, W.M. (1993) Proposed atomic structure of a truncated human immunodeficiency virus glycoprotein (HIV) gp120 derived by molecular modeling: target CD4 recognition and docking mechanism. Proc Natl Acad Sci USA, 90, 4186-4190.
2. Gabriel, J.L. and Mitchell, W.M. (1995) HIV GP120 Docking Interactions and Inhibitor Design Based on an Atomic Structure Derived by Molecular Modeling Using the DREIDING II Force Field, in Protein Folds, A Distance-based Approach. Boca Raton, CRC Press.
3. Mayo, S.L., Olafson, B.D. and Goddard, W.A., III. (1990) Dreiding: a generic force field for molecular simulations. J. Phys Chem, 94, 8897-8909.
4. Rappe, A.K. and Goodard, W.A., III. (1993) The charge equilibration method for calculating atomic charges. Biograf Reference Manual, pp 25, Molecular Simulations, Inc., 1994, chap 3.
5. Ryu, S.-E., Kwong, P.D., Trunah, A., Porter, T.G., Arthos, J., Rosenberg, M., Dai, X., Xuong, N.-h., Axel, R., Sweet, R.W and Hendrickson, W.A. (1990) Crystal structure of an HIV-binding recombinant fragment of human CD4. Nature (London), 348, 419-426.
6. Wang, J., Yan, Y., Garrett T.P.J., Liu, J., Rodgers, D.W., Garhck, R.L., Tarr, G.E., Husain Y., Reinherz, E.L. and Harrison, S.C. (1990) Atomic structure of a fragment of human CD4 containing two immunoglobulin-like domains. Nature (London), 348, 411-418.
7. Robinson, W.E., Jr. and Mitchell, W.M. (1990) Neutralization and enhancement of in vitro and in vivo HIV and SIV infection. AIDS, 4, S151-S162.
8. Robinson, W.E., Montefiori, D.C. and Mitchell, W.M. (1987) Evidence that mannosyl residues are involved in Human Immunodeficiency Virus Type I (HIV-1) pathogenesis. AIDS Res Human Retroviruses, 3, 265-282.
9. Kang, C.-Y. Hariharan, K., Nara, P.L., Sodroski, J. and Moore, J.P. (1994) Immunization with a soluble CD4-gp120 complex preferentially induces neutralizing anti-human immunodeficiency virus type 1 antibodies directed to conformation-dependent epitopes of gp120. J Virol, 68, 5854-5862.
10. Arthos, J., Deen, K.C., Chaikin, M.A., Fomwald, J.A. Sathe, G., Sattentau, Q.J., Clapham, P.R., Weiss, R.A., McDougal, J.S., Pietropaolo, C., Axel, R., Truneh, A., Maddon, P.J. and Sweet, R.W. (1989) Identification of the residues in human CD4 critical for the binding of HIV. Cell, 57, 469-481.
11. Bowman, M.R., MacFerrin, K.D., Schreiber, S.L. and Burakoff, S.J. (1990) Identification and structural analysis of residues in the V1 region of CD4 involved in interaction with human immunodeficiency virus envelope glycoprotein gp120 and class II major histocompatibility complex molecules. Proc Natl Acad Sci USA, 87, 9052-9056.
12. Lamarre, D., Ashkenazi, A., Fleury, S., Smith, D.H., Sekaly, R-P. and Capon, D.J. (1989) The MHC-binding and gp120-binding functions of CD4 are separable Science, 245, 743-746.
13. Olshevsky, U., Helseth, E., Furman, C., Li, J., Haseltine, W. and Sodroski, J. (1990) Identification of individual human immunodeficiency virus type I gp120 amino acids important for CD4 receptor binding. J. Virol, 64, 5701-5707.
14. Myers, G., Korber, B., Wain-Hobson, S., Jeang, K-T., Henderson, L.E. and Pavlakis II, G.N. (1994) Amino acid alignments, in Human Retroviruses and AIDS, II-A34-IIA-63, Los Alamos National Laboratory, Los Almos, NM.
15. Schols, D., Baba, M., Panwels, R., Desmyter, J. and DeClercq, E. (1989) Specific interaction of aurintricarboxylic acid with the human immunodeficiency virus/CD4 cell receptor. Proc Natl Acad Sci USA, 86, 3322-3326.
16. Finberg, R.W., Diamond, D.C., Mitchell, D.B., Rosenstein, Y., Soman, G., Norman, T.C., Schreiber, S.L. and Burakoff, S.J. (1990) Prevention of HIV-1 infection and preservation of CD4 function by the binding of CPFs to gp120. Science, 249, 287-291.
17. Saragovi, H.U., Fitzpatrick, D., Raktabutr, A., Nakanishi, H., Kahn, M. and Greene, M.I. (1991) Design and synthesis of a mimetic from an antibody complementarity-determining region. Science, 253, 792-795.
18. Chen, S., Chrusciel, R.A., Nakanishi, H., Raktabutr, A., Johnson, M.E., Sato, A., Weiner, D., Hoxie, J., Saragovi, H.U., Greene, M.I. and Kahn, M. (1992) Design and synthesis of a CD4 β-turn mimetic that inhibits human immunodeficiency virus envelope glycoprotein gp120 binding and infection of human lymphocytes. Proc Natl Acad Sci USA, 89, 5872-5876.
19. Yao, X.-J., Wainberg, M.A., Richard, M. and Pollak, M. (1991) The ability of suramin to block CD4-gp120 binding is reversed in the presence of albumin. Antimicrob Agents Chemother, 35, 2636-2638.
20. Cushman, M., Golebiewski, W.M., McMahon, J.B., Buckheit, Jr., R.W., Clanton, D.J., Weislow, O., Haugwitz, R.D., Bader, J.P., Graham, L. and Rice, W.G. (1994) Design, synthesis, and biological evaluation of cosalane, a novel anti-HIV agent which inhibits multiple features of virus reproduction. J Med Chem, 37, 3040-3050.
21. Omura, S., Tanaka, H., Matsuzaki, K., Ikeda, H. and Masuma, R. (1993) Isochromophilones I and II, novel inhibitors against gp120-CD4 binding from Penicillium sp. J Antibiotics, 46, 1908-1911.
22. Nishizawa, M., Yamagishi, T., Dutschman, G.E., Parker, W.B., Bodner, A.J., Kilkuskie, R.E., Cheng, Y-C. and Lee, K-H. (1989) Anti-AIDS agents, 1. Isolation and characterization of four new tetragalloylquinic acids as a new class of HIV reverse transcripts inhibitors from tannic acid. J Nat Products, 52, 762-768.
23. Nonaka, G-I., Nishioka, I., Nishizawa, M., Yamagishi, T., Kashiwada, Y., Dutschman, G.E., Bodner, A.J.. Kilkuskie, R.E., Cheng, Y-C. and Lee, K-H. (1990) Anti-AIDS agents, 2. Inhibitory effects of tannins on HIV reverse transcriptase and HIV replication in H9 lymphocyte cells. J Nat Products, 53, 587-595.
24. Weaver, J.L., Pine, P.S., Dutschman, G., Chen, Y-C., Lee, K-H. and Aszalos, A. (1992) Prevention of binding of rgp120 by anti-HIV tannins. Biochem Pharmacol, 43, 2479-2480.
25. Fisher, R.A., Bertonis, J.M., Meier, W., Johnson, V.A., Costopoulos, D.S., Liu, T., Tizard, R., Walker, B.D., Hirsch, M.S., Schooley, R.T. and Flavell, R.A. (1988) HIV infection is blocked in vitro by recombinant soluble CD4. Nature, 331, 76-78.
26. Hussey, R.E., Richardson, N.E., Kowalski, M., Brown, N.R., Chang, H-C., Siliciano, R.F., Dorfman, T., Walker, B., Sodroski, J. and Reinherz, E.L. (1988) A soluble CD4 protein selectively inhibits HIV replication and syncytium formation. Nature, 331, 78-81.
27. Deen, K.C., McDougal, J.S., Inacker, R., Folena-Wasserman, G., Arthos, J., Rosenberg, J., Maddon, P.J., Axel, R. and Sweet, R.W. (1988) A soluble form of CD4 (T4) protein inhibits AIDS virus infection. Nature, 331, 82-84.
28. Traunecker, A., Luke, W. and Karjalainen, K. (1988) Soluble CD4 molecules neutralize human immunodeficiency virus type 1. Nature, 331, 84-86.
29. Watanabe, M., Reimann, K.A., DeLong, P.A., Liu, T., Fisher, R.A. and Letvin, N.L. (1989) Effect of recombinant soluble CD4 in rhesus monkeys infected with simian immunodeficiency virus of macaques. Nature, 337, 267-270.
30. Werner, A., Winskowsky, G. and Kurth, R. (1990) Soluble CD4 enhances simian immunodeficiency virus SIVagm infection. J. Virol, 64, 6252-6256.
31. Schooley, R.T., Mengan, T.C., Gaut, P., Hirsch, M.S., Holodmy, M., Flynn, T., Liu, S., Byington, R.E., Henochowicz, S., Gubish, E., Spriggs, D., Kufe, D., Schindler, J., Dawson, A., Thomas, D., Hanson, D.G., Letwin, B., Liu, T., Gulinello, J , Kennedy, S., Fisher, R. and Ho, D.D. (1990) Recombinant soluble CD4 therapy in patients with the Acquired Immunodeficiency Syndrome (AIDS) and AIDS-related complex: a Phase I-II escalating dosage trial. Ann Intern Med, 112, 247-253.
32. Kahn, J.O., Allan, J.D., Hodges, T.L., Kaplan, L.D , Arri, C.J., Fitch, H.F., Izu, A.E., Mordenti, J., Sherwin, S.A., Groopman, J.E. and Volberding, P.A. (1990) The safety and pharmacokinetics of recombinant soluble CD4 (rCD4) in subjects with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex: a Phase I study. Ann Intern Med, 112, 254-261.
33. Tramont, E.D. and Redfield, R.R. (1990) Soluble CD4: the first step. (Editorial.) Ann Intern Med, 112, 241-242.
34. Daar, E.S., Li, X.L., Moudgil, T. and Ho, D.D. (1990) High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc Natl Acad Sci USA, 87, 6574-6578.
35. Bugelski, P.J., Solleveld, H.A., Fong, K.L., Klinkner, A.M., Hart, T.K. and Morgan, D.G. (1992) Myeloma-like cast nephropathy caused by human recombinant soluble CD4 (sCD4) in monkeys. Am J Pathol, 140, 531-537.
36. Embretson, J , Zupancic, M., Ribas, J L., Burke, A., Racz, P., Tenner-Racz, K. and Haase, A. T. (1993) massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature, 362, 359-362.
37. Pantaleo, G., Graziosi, C., Demarest, J.F., Butini, L., Montroni, M., Fox, C.H., Orenstein, J.M., Kotler, D.P. and Fauci, A.S. (1993) HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature, 362, 355-358.
38. Phair, J.P. (1993) Estimating prognosis in HIV-1 infection. Ann Int Med, 118, 742-744.
39. Mitchell, W.M. and Gabriel, J.L. (1993) Cleavage of the GR*AFV sequence of GP120 results in a predicted conformational change leading to tighter CD4 binding. Ninth International Conference on AIDS, Berlin, Germany, WS-A01-6.